Skip to main content

REVIEW article

Front. Immunol., 20 August 2021
Sec. Cancer Immunity and Immunotherapy
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.699746

Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

Ehsan Razeghian1 Wanich Suksatan2 Heshu Sulaiman Rahman3,4 Dmitry O. Bokov5,6 Walid Kamal Abdelbasset7,8 Ali Hassanzadeh9 Faroogh Marofi10 Mahboubeh Yazdanifar11 Mostafa Jarahian12*
  • 1Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, Iran
  • 2Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand
  • 3Department of Physiology, College of Medicine, University of Suleimanyah, Suleimanyah, Iraq
  • 4Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaimaniyah, Iraq
  • 5Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russia
  • 6Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russia
  • 7Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia
  • 8Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt
  • 9Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • 10Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran
  • 11Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, United States
  • 12Toxicology and Chemotherapy Unit (G401), German Cancer Research Center, Heidelberg, Germany

Citation: Razeghian E, Suksatan W, Sulaiman Rahman H, Bokov DO, Abdelbasset WK, Hassanzadeh A, Marofi F, Yazdanifar M and Jarahian M (2021) Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. Front. Immunol. 12:699746. doi: 10.3389/fimmu.2021.699746

Received: 24 April 2021; Accepted: 05 August 2021;
Published: 20 August 2021; Retracted: 04 September 2023.

Edited by:

Fabrizio Mattei, National Institute of Health (ISS), Italy

Reviewed by:

Michael Kalafatis, Cleveland University, United States
Thomas Griffith, University of Minnesota Twin Cities, United States
Download